SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (1131)10/26/2006 5:30:09 AM
From: nigel bates  Respond to of 3557
 
>>Any hard evidence that Antisoma VTA candidate will be able to compete..<<

Not yet -

"No p-values were quoted as this trial, though a good-sized phase II with 70 patients, wasn't powered to show differences at statistically significant levels. Please note that we have disclosed the confidence intervals that accompany the hazard ratio for the comparison of treatments (see webcast of data on our website at www.ANTISOMA.com)..."



To: Miljenko Zuanic who wrote (1131)10/26/2006 8:56:30 AM
From: scaram(o)uche  Respond to of 3557
 
you asked for new stuff..... you did NOT ask that I know anything about its relevance before I posted.

:-)


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News